| Document |
Document Title |
|
JP2013531647A |
Disclosed herein are methods of preventing or treating inflammatory diseases using sulfonamide analogs of 3-aminolactam compounds, each with aromatic "tail groups". Compounds as defined by formulae (I) and (I'), and the medical uses of t...
|
|
JP2013531657A |
A process for making a hydrogenated product comprising caprolactone (CLO) and 1,6-hexanediol (HDO) and derivatives thereof from adipic acid (AA) obtained from fermentation broths containing diammonium adipate (DAA) or monoammonium adipat...
|
|
JP2013531656A |
Processes for making hydrogenated products including caprolactame (CL) caprolactone (CLO) or 1,6-hexanediol (HDO) and derivative thereof from monoammonium adipate (MAA) and/or adipic acid (AA) obtained from a clarified diammonium adipate...
|
|
JP5258561B2 |
The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated *...
|
|
JP5258790B2 |
Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases,...
|
|
JP5254836B2 |
The present invention provides an efficient synthetic process for making benazepril and analogues thereof by having an intermediate compound undergo epimerization and kinetic resolution.
|
|
JP5248779B2 |
The invention relates inter alia to a compound of general formula (I) or (I'): wherein X is -CO-R 1 or -SO 2 -R 2 , R 1 is an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 4 to 20 carbon atoms (for examp...
|
|
JP5249033B2 |
|
|
JP5252614B2 |
The invention is directed to nonpeptide substituted benzazepines of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased v...
|
|
JP5251885B2 |
[Problems] To provide a compound which is useful as an NMDA receptor antagonist. [Means for solution] The present inventors have studied a compound having an NMDA receptor antagonistic action, and confirmed that the fused indane compound...
|
|
JP5242422B2 |
Resorcinol-blocked isocyanate compositions are derived from the reaction between a resorcinol compound and at least two different isocyanate compounds. The resorcinol-blocked isocyanate compositions may have two or more unblocking temper...
|
|
JP5244149B2 |
The present invention provides a compound of the following formula (I) below. This compound (I) can be produced by reacting a 2,2'-dimethylene bromide-1,1'-binaphthyl derivative, which can be produced by a relatively small number of proc...
|
|
JP2013141659A |
To provide a reaction apparatus which can inhibit rapid oxidation or combustion reaction caused by mixing a reaction gas present in a reactor with a regeneration gas present in a regenerator.The reaction apparatus includes: a fluidized b...
|
|
JP5236588B2 |
Preparing a bicyclo[4.2.0]octa-1(6),2,4-triene compound (IV) comprises: cyclization reaction of an ethyl-benzene compound (V) in the presence of a catalyst/ligand comprising a palladium catalyst and an organic phosphine (including tri-te...
|
|
JP5237810B2 |
The present invention provides 6-substituted-2,3,4,5-tetrahydro- 1 H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder,...
|
|
JP2013136523A |
To provide a method for producing ε-caprolactam, capable of obtaining high quality ε-caprolactam from crude ε-caprolactam by using evaporative crystallization in good yield.This production method of ε-caprolactam comprises: a purific...
|
|
JP5231693B2 |
The amine content of amine-contaminated N-substituted lactams is reduced by treatment with an acidic macroporous cation exchanger.
|
|
JP5232861B2 |
Disclosed are compounds of the formula I wherein A, Y, R1, R2, R3, R4 and R5 are defined, suitable for treating diseases and symptoms of diseases caused at least to some extent by stimulation of bradykinin-B1 receptors, the preparation t...
|
|
JP5232771B2 |
The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, poly...
|
|
JP5235406B2 |
An integrated process combines olefin epoxidation with production of cyclohexanone and cyclohexanol for nylon. Cyclohexanone and cyclohexanol normally produced by the oxidation of cyclohexane, in which cyclohexyl hydroperoxide is generat...
|
|
JP2013133284A |
To provide a method for producing ε-caprolactam, by which the ε-caprolactam having high quality and having reduced impurities can be produced from crude ε-caprolactam containing impurities in a good yield with saved energy.The method ...
|
|
JP2013528201A |
Disclosed herein are methods of preventing or treating inflammatory diseases using sulfonamide analogs of 3-aminolactam compounds, each with aromatic "tail groups". Compounds as defined by formulae (I) and (I'), and the medical uses of t...
|
|
JP2013129610A |
To provide a method for producing ε-caprolactam that has a process in which ε-caprolactam is crystallized while controlling scaling in a vessel.The method for producing ε-caprolactam includes a crystallization step of crystallizing ε...
|
|
JP2013129609A |
To provide a method for producing ε-caprolactam that has a process in which ε-caprolactam is crystallized while controlling scaling in a vessel.The method for producing ε-caprolactam includes a crystallization step of crystallizing ε...
|
|
JP2013128919A |
To provide a method for removing impurities, whereby solid matter or a component can be removed from the interior of a distillation column when a target matter is being isolated from a mixture gas containing solid matter or a component c...
|
|
JP2013527124A |
Carbamate linked prodrugs of meptazinol and other opioid analgesics are provided. The prodrug moiety may comprise a single amino acid or short peptide. Additionally, the present invention relates to methods for reducing gastrointestinal ...
|
|
JP5223864B2 |
The present invention provides compounds having excellent 11²-HSD1 inhibitory activity. A compound represented by the following formula (I): [wherein X 1 represents an oxygen atom, or the formula -(CR 11 R 12 ) p -, etc., Y 1 represents...
|
|
JP2013525438A |
Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that are useful in treating a number of disease...
|
|
JP5216697B2 |
Preparation of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (I), comprises (a) transforming (3,4-dimethoxyphenyl)acetic acid (IV) into an amide compound (V), and (b) subjecting (V) to a cyclization reaction in an acidic condition to g...
|
|
JP2013119046A |
To provide a reaction apparatus in which catalytic activity of a solid catalyst is hardly deteriorated.The reaction apparatus 1 includes: a reactor 2 in which gaseous raw materials are reacted chemically with each other in the presence o...
|
|
JP2013523599A |
The present invention concerns dicarboxylic acid linked amino acid and peptide prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, decreasing the adverse GI side effe...
|
|
JP2013119539A |
To provide a method for obtaining efficiently high-purity ε-caprolactam, concerning a method for purifying ε-caprolactam by distillation after concentrating recovered ε-caprolactam-containing water.In this method for purifying recover...
|
|
JP2013116431A |
To provide a reactor which can smoothly discharge solid catalysts collected by dust collectors to the outside of a reaction vessel.This reactor comprises: the reaction vessel 20; a fluid bed arranged in the reaction vessel 20 and compose...
|
|
JP5211318B2 |
To further introduce a substituent into the α position on a side introduced with the substituent of a cyclic nitrogen compound substituted in the α position. The method for producing α,α-di-substituted cyclic nitrogen-containing comp...
|
|
JP5208917B2 |
A process for preparing compounds of formula I or a solvate or hydrate thereof, where R, R1, R2, R3 and R5 have the meanings as indicated in the specification. Such compounds are useful in the treatment of a number of conditions associat...
|
|
JP5209670B2 |
Novel heterocyclo compounds useful as inhibitor of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating del...
|
|
JP5208412B2 |
The present invention relates to a benzenesulfonamide derivative of formula (I), which is useful as an active ingredient of pharmaceutical preparations. The benzenesulfonamide derivatives of the present invention have CCR3 (CC type chemo...
|
|
JP5209471B2 |
The invention provides compounds, pharmaceutical compositions and uses of compounds and salts thereof of general formula (I), for the preparation of a medicament for treatment of an inflammatory disorder, but excluding (S)-3-(1′-methyl...
|
|
JP5204231B2 |
Amide compounds (I) and their enantiomers, diastereomers, mixtures and salts, preferably with organic or inorganic acids or bases, are new. Amide compounds of formula (R 5>-A-R 4>-B1-R 3>-A-D1-Y1-N(R 2>)-SO 2-R 1>) (I) and their enantiom...
|
|
JP5203360B2 |
Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for ...
|
|
JP2013095700A |
To provide a method for producing a lactam compound (III) and/or an amide compound (IV) with an excellent selectivity by converting a lactone compound (I) with an excellent conversion.By making a lactone compound (I) and ammonia or an am...
|
|
JP5198877B2 |
It is an object of the present invention to provide 2-iminocarboxylic acid derivatives, and a practically suitable industrial method for producing benzazepinones in a short process under mild conditions. The present invention provides a ...
|
|
JP5198780B2 |
|
|
JP5199997B2 |
|
|
JP5192730B2 |
|
|
JP2013514335A |
The invention relates to a process for treating an aqueous solution containing epsilon-caprolactam, ammonium sulphate and one or more other impurities, comprising one or more organic impurities from a caprolactam production process and o...
|
|
JP2013075290A |
To provide a mist separation device capable of fully catching mist contained in a vaporized gas.The mist separation device includes: a plurality of tubes; a shell for housing the plurality of tubes; an inflow unit disposed in the inner w...
|
|
JPWO2011071136A1 |
5-HT2CA therapeutic agent for fibromyalgia containing a receptor agonist as an active ingredient. [Selection diagram] Fig. 4
|
|
JP2013512272A |
Compounds of the formula I: wherein m, n, X1, X2, Y1, Y2, R1 and R2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
|
|
JP5165568B2 |
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, d...
|
